BioXcel Therapeutics, Inc. Cash and Cash Equivalents
BioXcel Therapeutics, Inc. (BTAI) had Cash and Cash Equivalents of $12.84 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-13
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $12.84M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $17.18M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $28.41M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $36.18M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $12.84M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $17.18M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $28.41M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $36.18M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $17.43M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $31.01M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $29.85M 10-K · filed 2026-03-27 |
| 2024-09-30 | $40.39M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $56.27M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $74.14M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $65.22M 10-K · filed 2025-03-28 |
| 2023-09-30 | $89.96M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $127.55M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $165.52M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $193.72M 10-K · filed 2024-03-22 |
| 2022-09-30 | $232.31M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $233.45M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $200.44M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $232.97M 10-K · filed 2023-03-16 |
| 2021-09-30 | $252.91M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $273.06M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $194.01M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $213.12M 10-K · filed 2022-03-11 |
| 2020-09-30 | $233.43M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $65.50M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $80.08M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $32.43M 10-K · filed 2021-03-12 |
| 2019-09-30 | $40.25M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $29.96M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $36.30M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $42.56M 10-K · filed 2020-03-09 |
| 2018-09-30 | $47.12M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $50.35M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $55.47M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $887.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |